EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia

Matthew D Hickey iD, Nathanael Gistand, Janet Grochowski, Francis Mayorga-Munoz, Elizabeth Imbert iD, John D Szumowski iD, Jon Oskarsson, Mary Shiels, Samantha Dilworth, Ayesha Appa iD, Diane V Havlir, Monica Gandhi iD und 1 weitere

Clinical Infectious Diseases · 30.04.2025 · 80 (4) · 864-870

DOI: 10.1093/cid/ciae500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.10.2024. Verfasst von Matthew D Hickey und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of HIV, Infectious Disease, & Global Medicine, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Viremia, Anti-HIV Agents, Rilpivirine. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously demonstrated at the Ward 86 human immunodeficiency virus (HIV) clinic in San Francisco that long-acting (LA) cabotegravir (CAB)/rilpivirine (RPV) (LA-CAB/RPV) can rapidly lead to viral suppression in people with HIV (PWH) with viremia due to adherence challenges. We now evaluate the durability of viral suppression in this population.

Methods

We conducted a retrospective cohort study of PWH who started LA-CAB/RPV with viremia (HIV RNA viral load ≥50 copies/mL) before December 2022. Our primary outcome was viral suppression (viral load <50 copies/mL) with LA-CAB/RPV persistence (not discontinued or late by >14 days) at 48 weeks, using the viral load closest to 48 ± 8 weeks. We also describe viral failure, defined as a <2-log decline in viral load at 4 weeks or a viral load ≥200 copies/mL after initial viral suppression with emergent CAB- or RPV-associated resistance mutations; overall 48-week viral suppression including those switched to alternative antiretroviral therapy (ART).

Results

Fifty-nine PWH initiated LA-CAB/RPV with viremia and were included in the analysis; 49% had a CD4 cell count <200/µL, and the median baseline viral load was 42 900 copies/mL (quarter 1–quarter 3, 5272–139 038). At 48 weeks, 47 PWH met the primary outcome of viral suppression with LA-CAB/RPV persistence (80% [95% confidence interval, 67%–89%]). Five had viral failure with resistance (3 with RPV-associated and 2 with CAB- and RPV-associated mutations), and 1 was lost to follow-up. At week 48, 2 of those with viral failure were suppressed on alternative regimens (lenacapavir + bictegravir/tenofovir alafenamide/emtricitabine and CAB + lenacapavir). The overall viral suppression at week 48 with either LA-CAB/RPV or alternative ART was 92% (54 of 59).

Conclusions

In PWH initiating LA-CAB/RPV with initial viremia, 48-week viral suppression (<50 copies/mL) was seen in 92%. LA ART can be an important tool for improving viral suppression among patients who face adherence challenges to oral ART.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsViremiaAnti-HIV AgentsRilpivirinePyridonesHumansViral LoadFemaleRetrospective StudiesMaleAdultMiddle AgedDrug Resistance, ViralHIV-1Diketopiperazines

Stichwörter der Autor:innen

HIV/AIDSinjectable cabotegravir and rilpivirinelong-acting antiretroviral therapyviral suppressionviremia

Substanzen

Anti-HIV AgentscabotegravirRilpivirinePyridonesDiketopiperazines

Autor:innen und Institutionen

  • Division of HIV, Infectious Disease, & Global Medicine, University of California, San Francisco, California, USA.
  • Division of Infectious Disease, San Francisco VA Medical Center, University of California, San Francisco, California, USA.

ORCID-Profile: Matthew D Hickey, Elizabeth Imbert, John D Szumowski, Ayesha Appa, Monica Gandhi, Katerina Christopoulos

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • NIMH NIH HHS
  • National Institute of Mental Health
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Hickey, M. D., Gistand, N., Grochowski, J., Mayorga-Munoz, F., Imbert, E., Szumowski, J. D., Oskarsson, J., Shiels, M., Dilworth, S., Appa, A., Havlir, D. V., Gandhi, M., & Christopoulos, K. (2025). Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia. Clinical Infectious Diseases, 80(4), 864-870. https://doi.org/10.1093/cid/ciae500

Vancouver

Hickey MD, Gistand N, Grochowski J, Mayorga-Munoz F, Imbert E, Szumowski JD, et al. Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia. Clinical Infectious Diseases. 2025;80(4):864-870. doi:10.1093/cid/ciae500

BibTeX
@article{Hickey2025,
  author = {Hickey, Matthew D and Gistand, Nathanael and Grochowski, Janet and Mayorga-Munoz, Francis and Imbert, Elizabeth and Szumowski, John D and Oskarsson, Jon and Shiels, Mary and Dilworth, Samantha and Appa, Ayesha and Havlir, Diane V and Gandhi, Monica and Christopoulos, Katerina},
  title = {Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {4},
  pages = {864--870},
  doi = {10.1093/cid/ciae500}
}
Kostenlos starten →